Hematology-OncologyMRD陰性化multiple myeloma
Slow but Steady: t(11;14) Myeloma Shows Superior Outcomes Despite Delayed MRD Negativity with Quadruplet Therapy
By MedXY|Apr 24, 2026
t(11;14) multiple myeloma exhibits slower MRD clearance but superior PFS with quadruplet therapy and MRD-adapted management, challenging conventional response kinetics paradigms.